Tumor-targeted CD40 agonism represents an attractive strategy for cancer immunotherapy (CIT) as it promotes dendritic cell (DC) activation and concomitant tumor-specific T cell priming without causing systemic side effects. We developed the bispecific CD40 agonistic antibody CEA-CD40. which triggers CD40 stimulation exclusively in the presence of carcinoembryonic antigen (CEA). a glyc... https://www.chiggate.com/tenga-flip-orb-masturbator-fashion/